CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00046787
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:15.050276+00:00
- Published At
- 2011-10-20T00:00:00+00:00
- Record Updated At
- 2011-10-20
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["SCLC", "Carcinoma, Small Cell"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2011-10-20"- protocolSection.identificationModule.nctId
"NCT00046787"- protocolSection.identificationModule.officialTitle
"Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 \u0026 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.